[Featured Stock] Sinopex Rises on Success of Korea's First Artificial Kidney Dialysis Clinical Trial
Sinopex's stock price is showing strong performance in early trading. The news of successfully completing clinical trials for the blood filter (dialysis) used in artificial kidneys for the first time in Korea is believed to have driven the stock price up.
As of 9:10 AM on the 7th, Sinopex is trading at 5,410 KRW, up 11.32% (550 KRW) compared to the previous session.
Sinopex announced through a press release that the patient-use clinical trial conducted on 50 hemodialysis patients at five major hospitals in Korea was successfully completed last week. This is the first official clinical trial conducted with a domestically produced blood dialysis filter for artificial kidneys, marking 59 years since hemodialysis began in Korea.
Hot Picks Today
"Should Get at Least 45 Million Won Salary" "Can't Give Up on Large Companies"... Young People Say There Are No Places to Apply
- Unemployment Benefits to Drop from 1.98 Million to 1.76 Million Won per Month...Employment Insurance Premium Rate to Rise from 1.8% to 2%
- Packed Crowds with “It’s So Cheap!”... Japan Travel by UK Millennials & Gen Z Surges 25% in a Year
- "Only One Restroom Break per Semester During Class"…Controversy Over Chinese High School Regulations
- When "Cutting Down Reserved Tents" Brings Relief: Local Governments Take Action Against Escalating 'Reserved Tent' Problem
Currently, blood filters for artificial kidneys are entirely imported under duty-free conditions, but Sinopex has succeeded in domestic production and obtained product approval from the Ministry of Food and Drug Safety in March last year.
![[Featured Stock] Sinopex Rises on Success of Korea's First Artificial Kidney Dialysis Clinical Trial](http://www.asiae.co.kr/news/img_view.htm?img=2025030509433154739_1741135411.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
